Kiniksa Pharmaceuticals International (KNSA) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 125.8% versus a gain of 42.2%. Over five years, KNSA leads with a +706.0% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.38 billion), about 1.1 times the size, while Kiniksa Pharmaceuticals International is growing revenue faster (+60.1% vs -89.4%).
On valuation, Kiniksa Pharmaceuticals International trades at a lower forward P/E (45.9x vs 348.8x for Protagonist Therapeutics). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KNSA | PTGX |
|---|---|---|
| Share price | $93.90 | $121.40 |
| Market cap | $7.38B | $7.92B |
| 1-day change | +0.38% | -2.11% |
| YTD return | +127.62% | +39.00% |
| 1-year return | +125.82% | +42.15% |
| 5-year return | +705.97% | +265.00% |
| P/E ratio (TTM) | 71.13 | 25.67 |
| Forward P/E | 45.91 | 348.79 |
| EPS (TTM) | $1.32 | $4.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $677.56M | $46.02M |
| Revenue growth (YoY) | +60.09% | -89.41% |
| Net income (latest FY) | $59.01M | $-130.15M |
| Gross margin | 88.54% | — |
| Operating margin | 11.40% | -343.63% |
| Net margin | 8.71% | -282.83% |
| 52-week high | $99.31 | $160.81 |
| 52-week low | $37.02 | $77.00 |
| Distance from 52-week high | -5.45% | -24.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +18.82% | +50.21% |
| Average volume | 664.53K | 668.45K |
| Shares outstanding | 48.84M | 65.27M |
| Employees | 366 | 149 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed PTGX by 83.7 percentage points over the past year.
- Kiniksa Pharmaceuticals International trades at a higher earnings multiple (71.1x vs 25.7x trailing P/E).
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Kiniksa Pharmaceuticals International grew revenue faster in its latest fiscal year (+60.09% vs -89.41%).
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees
KNSA vs PTGX FAQ
Which is bigger, Kiniksa Pharmaceuticals International or Protagonist Therapeutics?
Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.38B for Kiniksa Pharmaceuticals International (KNSA).
Which stock has performed better over the past year, KNSA or PTGX?
KNSA returned +125.82% over the past 12 months, compared with +42.15% for PTGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, KNSA or PTGX?
PTGX has the lower trailing P/E at 25.7, versus 71.1 for KNSA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Kiniksa Pharmaceuticals International and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.